The coronavirus disease 2019 (COVID-19) is a novel illness, which is not fully understood. Whether an individual has traveled outside their respective country or never left their community, COVID-19 is a highly contagious illness, which can result in high death rates. Biobanks will play a role in providing tools to examine data from those receiving treatment along with reviewing the current and long treatment outcomes associated with this novel coronavirus disease. A diverse, global network made up of laboratory scientists, clinical researchers, epidemiologists, data science teams, physicians, and so on must have a standardized, collaborative, virtual biobanking solution to share clinical expertise and evidence-based solutions. This virtual biobank must be centrally managed to ensure standardized quality assurance and quality control efforts. Virtual biobanks will eliminate the need to transport samples between two locations for a specific study, minimizing the risk of contamination. It is necessary for virtual biobanks to upload imaging data from those patients diagnosed with COVID-19. Standardized, collected information will be essential in the area of discovery and validation of disease markers as well as novel therapeutic strategies. It is essential for biobanks to collect COVID-19 specimens along with corresponding clinical and demographic data from COVID-19 diagnostic testing. Because COVID-19 is an acute respiratory illness, proper collection procedures must be in place to collect respiratory samples for biobanking purposes. A preconfigured purpose-built COVID-19 Laboratory Information Management System (LIMS) is an efficient tool to seamlessly manage a data sharing network. Data entered into LIMS will be beneficial in designing much needed clinical trials to address any unmet needs to better address clinical treatment and outcomes. The partners or entities associated with the COVID-19 data sharing network will be able to effectively communicate, view data, and images associated with their respective research interest to advance COVID-19 research and data driven, clinical care.

中文翻译：

---

针对COVID-19大流行的生物库数据共享解决方案。

冠状病毒病2019（COVID-19）是一种新型疾病，目前尚未完全了解。无论个人是出国旅行还是从未离开社区，COVID-19都是高传染性疾病，可能导致高死亡率。生物库将在提供工具以检查来自接受治疗者的数据以及审查与这种新型冠状病毒疾病相关的当前和长期治疗结果方面发挥作用。由实验室科学家，临床研究人员，流行病学家，数据科学团队，医师等组成的多元化全球网络必须拥有标准化的协作虚拟生物银行解决方案，才能共享临床专业知识和基于证据的解决方案。该虚拟生物库必须进行集中管理，以确保标准化的质量保证和质量控制工作。虚拟生物库将消除针对特定研究在两个位置之间运输样本的需要，从而将污染风险降到最低。虚拟生物库必须上传诊断为COVID-19的患者的影像数据。在疾病标志物的发现和验证以及新型治疗策略方面，标准化的收集信息将至关重要。对于生物库而言，从COVID-19诊断测试中收集COVID-19标本以及相应的临床和人口统计学数据至关重要。由于COVID-19是一种急性呼吸道疾病，因此必须采取适当的收集程序来收集呼吸道样本以用于生物储备。预先配置的专用COVID-19实验室信息管理系统（LIMS）是无缝管理数据共享网络的有效工具。输入LIMS的数据将有助于设计急需的临床试验，以解决任何未满足的需求，从而更好地应对临床治疗和结果。与COVID-19数据共享网络关联的合作伙伴或实体将能够有效地交流，查看与其各自研究兴趣相关的数据和图像，从而推进COVID-19研究和数据驱动的临床护理。